Zilebesiran
ALN-AGT01First RNAi therapeutic for hypertension. Quarterly or biannual dosing reduces hepatic angiotensinogen production.
Target: AGT GalNAc-conjugated siRNA (RNAi therapeutic) Alnylam Pharmaceuticals Cardiometabolic
When will we know if it works?
Fresh est.A positive readout makes AGT a validated target for the first time. Hover the badge above for what the confidence level means.
1
Phase 3 trials
1 active · 0 completed
6
Total trials
P2: 4 · P1: 1
11,000
Max trial size
across 4 indications
1
Sponsors at target
incl. 1 other asset
What does it do?
AGT — Angiotensinogen
Modality: GalNAc-conjugated siRNA (RNAi therapeutic)
Program: KARDIA
The 1 Phase 3 trial
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT07181109 | High Risk Cardiovascular Disease; Hypertension | 11,000 | RECRUITING | 2025-09-22 | 2030-09-30 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2023 | partnership | Roche | $310M upfront + $1.4B milestones (worldwide co-dev/co-com ex-US) |
What's the case for and against?
✓ What's working in its favor
- Phase 1 KARDIA-1: -22 mmHg systolic at single dose, sustained 6+ months
- Phase 2: durable BP reduction with quarterly dosing
Who else is racing? — 1 other asset at AGT
| Asset | Sponsor | Status |
|---|---|---|
| IONIS-AGT-LRx | Ionis | P2 — different ASO at same target |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.